COVID-19 Vaccine Studies Should Look Beyond Neutralizing Antibodies To Assess Variants’ Impact
Executive Summary
Cellular responses and other potential immune correlates of protection could be better measurements of efficacy, Janssen’s vaccine discovery head argues at BIO.
You may also be interested in...
EMA Considers How To Verify Potency Of Next-Generation COVID-19 Vaccines
Companies approaching the European Medicines Agency with their development plans for new COVID-19 vaccines are being asked to consider immunobridging studies if placebo-controlled trials are not feasible.
BIO 2021 Notebook: Going Fast And Being Precise
News and views from day three of the BIO Digital annual meeting include Amgen’s CEO on speedy development and NIH’s chief on bringing personalized medicine to COVID vaccines.
BIO 2021 Notebook: Going Fast And Being Precise
News and views from day three of the BIO Digital annual meeting include Amgen’s CEO on speedy development and NIH’s chief on bringing personalized medicine to COVID vaccines.